SAB Biotherapeutics, Inc. (SABS)
| Market Cap | 262.04M +137.0% |
| Revenue (ttm) | n/a |
| Net Income | -21.79M |
| EPS | -1.56 |
| Shares Out | 90.99M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 814,536 |
| Open | 2.590 |
| Previous Close | 2.600 |
| Day's Range | 2.554 - 2.930 |
| 52-Week Range | 2.440 - 5.150 |
| Beta | 0.58 |
| Analysts | Strong Buy |
| Price Target | 11.64 (+304.17%) |
| Est. Earnings | Nov 12, 2026 |
About SABS
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.
Financial Performance
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for SABS stock is "Strong Buy." The 12-month stock price target is $11.64, which is an increase of 304.17% from the latest price.
News
SAB Biotherapeutics Transcript: Chardan's 10th Annual Healthcare Conference
Healios outlined an upcoming Japan ARDS filing and global phase III plans, supported by scalable cell manufacturing. The engineered-cow antibody program reported redosing and early Type 1 diabetes signals; pivotal SAFEGUARD enrollment was near completion.
SAB BIO to Participate in Chardan 10th Annual Healthcare Conference
MIAMI, Oct. 14, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 d...
SAB Biotherapeutics granted Fast Track designation for SAB-142
SAB Biotherapeutics (SABS) announced that the FDA has granted Fast Track designation to SAB-142, a potentially disease-modifying immunotherapy being developed for the treatment of individuals with new...
SAB BIO Receives FDA Fast Track Designation for SAB-142 in Stage 3 Type 1 Diabetes
Fast Track designation recognizes the potential of SAB-142 to address an unmet medical need for people with Stage 3 type 1 diabetes
SAB Biotherapeutics Slides: Corporate presentation
SAB Biotherapeutics has posted slides in relation to its latest quarterly earnings report, which was published on October 10, 2026.
SAB BIO to Present SAB-142 Data at the Inaugural Breakthrough T1D Clinical & Research Congress
MIAMI, Oct. 01, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 d...
SAB Biotherapeutics Slides: Corporate presentation
SAB Biotherapeutics has posted slides in relation to its latest quarterly earnings report, which was published on September 30, 2026.
SAB BIO to Present SAB-142 Data at the 62nd Annual Meeting of the European Association for the Study of Diabetes
MIAMI, Sept. 22, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 ...
SAB Biotherapeutics Transcript: Citigroup’s Biopharma Back to School Summit 2026
SAFETYGUARD pivotal study for SAB-142 is on track, with last patient enrollment expected in Q4 2026 and top-line data in the second half of 2027. The commercial opportunity is estimated at $4 billion in the U.S., with significant expansion potential, and the company is well-funded through 2028.
SAB Biotherapeutics Slides: FY 2026
SAB Biotherapeutics has posted slides in relation to its FY 2026 quarterly earnings report, which was published on September 10, 2026.
SAB BIO to Participate in Upcoming Investor Conferences
MIAMI, Sept. 01, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 ...
SAB Biotherapeutics Earnings Call Transcript: Q2 2026
SAB-142 clinical programs advanced with strong enrollment in SAFEGUARD and PRISE studies, supported by robust cash reserves and operational runway through 2028. Financials reflect increased R&D and G&A expenses, while regulatory and market momentum for disease-modifying T1D therapies continues.
SAB Biotherapeutics Earnings release: Q2 2026
SAB Biotherapeutics released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
SAB Biotherapeutics Quarterly report: Q2 2026
SAB Biotherapeutics has published its Q2 2026 quarterly earnings report on August 6, 2026.
SAB BIO Reports Q2 2026 Financial Results and Provides Business Highlights
Over 60 clinical sites activated in registrational SAFEGUARD study of SAB-142 in Stage 3 new onset type 1 diabetes; Enrollment remains on track for completion in Q4 2026, with topline data expected in...
SAB BIO to Host Second Quarter 2026 Financial Results Conference Call and Webcast on August 6, 2026, 08:30 AM ET
MIAMI, July 30, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 d...
Breakthrough T1D Awards Grant to Support PRISE‑hATG Study of SAB‑142 in Stage 3 Type 1 Diabetes
MIAMI, July 07, 2026 (GLOBE NEWSWIRE) -- Breakthrough T1D, the leading global type 1 diabetes (T1D) research and advocacy organization and SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage bi...
SAB Biotherapeutics initiated with an Overweight at Barclays
Barclays analyst Eliana Merle initiated coverage of SAB Biotherapeutics (SABS) with an Overweight rating and $13 price target The type 1 diabetes market is large and SAB-142 could have a…
SAB BIO to Present Data on SAB-142 at The American Diabetes Association's 2026 Scientific Sessions and FOCIS 2026 Annual Meeting
Data will highlight deeper mechanistic insights and long-term dosing potential of SAB-142, a fully human multi-specific ATG for newly diagnosed Stage 3 T1D Data will highlight deeper mechanistic insig...
SAB Biotherapeutics initiated with a Buy at Citi
Citi initiated coverage of SAB Biotherapeutics (SABS) with a Buy rating and $11 price target The firm says the company is redefining the type 1 diabetes treatment paradigm. SAB is…
SAB Biotherapeutics initiated with a Buy at Jefferies
Jefferies initiated coverage of SAB Biotherapeutics (SABS) with a Buy rating and $11 price target The company’s lead product SAB-142 is in a Phase 2b study for stage 3 type…
SAB Biotherapeutics Slides: Corporate presentation
SAB Biotherapeutics has posted slides in relation to its latest quarterly earnings report, which was published on May 13, 2026.
SAB Biotherapeutics price target raised to $10 from $7 at H.C. Wainwright
H.C. Wainwright analyst Emily Bodnar raised the firm’s price target on SAB Biotherapeutics (SABS) to $10 from $7 and keeps a Buy rating on the shares following the Q1 report.
SAB Biotherapeutics Earnings Call Transcript: Q1 2026
Lead candidate SAB-142 advanced to phase II-B with strong phase I data and regulatory de-risking. Q1 2026 ended with $217.6M in cash, supporting operations through 2028. SAFEGUARD trial enrollment is on track, and a manufacturing deal with Emergent BioSolutions supports future commercialization.
SAB Biotherapeutics Earnings release: Q1 2026
SAB Biotherapeutics released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.